[1
]
From National Amyloidosis Centre, Division of Medicine (J.D.G., A.D.W., C.C.Q., H.J.L.,
T.R., M.F., K.F., T.L., F.W.V., C.J.W., D.F.H., P.N.H.) and Barts Heart Centre, Institute
of Cardiovascular Science (J.C.M.), University College London, UK; Clinical Cardiovascular
Research Laboratory for the Elderly, Columbia University Medical Center, New York
(M.S.M., S.B., A.C.); Department of Cardiology and Department of Radiology, Brigham
and Women's Hospital and Harvard Medical School, Boston, MA (R.H.F., S.D.); Amyloidosis
Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere
Scientifico Policlinico San Matteo, and Department of Molecular Medicine, University
of Pavia, Italy (G.M., G.P., P.M.); Department of Cardiology, University Hospital
Henri Mondor, Amyloidosis Mondor Network, Creteil, France (T.D.); Division of Hematology,
Division of Cardiovascular Diseases, and Department of Radiology, Division of Nuclear
Medicine, Department of Medicine, Mayo Clinic, Rochester, MN (A.D., M.G., G.B.J.);
Amyloidosis Center, Boston University School of Medicine and Boston Medical Center,
MA (J.L.B., F.L.R.); Departments of Nuclear Medicine and Molecular Imaging (A.W.J.M.G.)
and Rheumatology and Clinical Immunology (B.P.H.), University of Groningen, University
Medical Center Groningen, The Netherlands; Department of Nuclear Medicine, S. Orsola-Malpighi
Hospital, and Cardiology Unit, Department of Experimental, Diagnostic and Specialty
Medicine, Alma Mater-University of Bologna, Italy (P.L.G., C.R.); and Yale University
School of Medicine, Section of Cardiovascular Medicine, New Haven, CT (E.J.M.).